228 Participants Needed

HPV Vaccine for Anal Cancer Prevention

Recruiting at 3 trial locations
MC
IS
GH
Overseen ByGrecia Higuerey
Age: 18+
Sex: Male
Trial Phase: Phase 2
Sponsor: University Health Network, Toronto
Must be taking: cART
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, if you are on cART (HIV treatment), you must be on a stable regimen for at least six months.

What data supports the effectiveness of the 9-valent HPV vaccine treatment for preventing anal cancer?

Research shows that HPV vaccines, including the 9-valent type, are effective in preventing anal HPV infections and related precancerous lesions, which are linked to anal cancer. The 9-valent vaccine covers HPV types found in most anal cancers, suggesting it should effectively prevent anal cancer when given before sexual activity begins.12345

Is the 9-valent HPV vaccine safe for humans?

The 9-valent HPV vaccine (9vHPV) has been shown to be safe and well tolerated in clinical studies, with a safety profile comparable to the earlier quadrivalent HPV vaccine. Some local reactions like swelling may occur, especially when given with other vaccines.678910

How is the 9-valent HPV vaccine unique for preventing anal cancer?

The 9-valent HPV vaccine is unique because it protects against nine types of HPV, including five additional cancer-causing types not covered by earlier vaccines, potentially preventing up to 95% of HPV-related anal cancers.67111213

What is the purpose of this trial?

Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) worldwide. Infection by certain high-risk oncogenic types of HPV (HR-HPV) is the major cause of several cancers in men, notably squamous cell carcinoma (SCC) of the anal canal. Rates of anal infection with these HR-HPV strains, and the resultant high-grade anal dysplasia and anal cancer are much higher in men who have sex with men (MSM) than in the general population. Co-infection with human immunodeficiency virus (HIV) further amplifies this burden, making the rates of anal SCC in HIV-positive MSM higher than the historic rates of cervical cancer prior to the adoption of routine cervical cytology screening. Despite these alarming statistics, there are no established protocols for optimal screening and treatment of anal HPV and cancer precursors, nor has there been any widespread rollout of organized screening programs anywhere in Canada. Further, not only does HPV directly cause significant disease in these men, but there is growing epidemiologic evidence that HPV infection may enhance sexual transmission of HIV. These significant knowledge gaps translate into fundamental deficiencies in care for HIV-positive MSM.The HPV Screening and Vaccine Evaluation in MSM (HPV-SAVE) study team was funded by the Canadian Institutes of Health Research (CIHR) via its Boys' and Men's Health Team Grant Competition. It aims to recruit a large group of MSM from various Ontario and Vancouver clinics, in order to carry out a number of different studies. The HPV-SAVE team brings together community and internationally-recognized experts in HPV and HIV disease and mucosal immunology, to better define the optimal approaches for primary and secondary prevention and treatment of HPV-associated anal disease among HIV-positive MSM, and to explore biological mechanistic evidence regarding the potential role of HPV as a co-factor for HIV transmission. This will yield critical information which can lead to improvement in the health of MSM, and will provide a foundation on which to build large-scale screening and treatment trials on a national level. A key part of this research program involves an analysis of the potential role played by the HPV vaccine in the overall management of HIV-positive MSM.Planned vaccine-related projects include:* A mixed-methods analysis of the knowledge, attitudes, and acceptability of HPV vaccination amongst HIV-positive MSM, through quantitative (e.g. cross-sectional survey) and qualitative (e.g. in-depth interviews) means.* A comprehensive assessment of the 9-valent HPV vaccine in HIV-positive MSM, including safety and immunogenicity, as well as its potential role in secondary prevention of high-grade anal dysplasia. This is the study on which the current proposal is based.

Research Team

IS

Irving Salit, MD

Principal Investigator

Toronto General Hospital, University Health Network

Eligibility Criteria

This trial is for HIV-positive men who have had sexual activity with men or both genders, are at least 18 years old, and have high-grade anal dysplasia (AIN-2 or -3). They must be willing to undergo standard ablative therapy and either be on a stable antiretroviral regimen or not planning to start one within six months. Participants need documented HIV infection and the ability to attend all study visits.

Inclusion Criteria

I have had sexual relations with men or both men and women.
I can go to all required clinic visits for the study.
I have had sexual activity with men or both men and women.
See 11 more

Exclusion Criteria

I have or had cancer in the genital, anal, rectal, or throat areas.
You are allergic to any ingredient in the HPV vaccine, like yeast or aluminum.
I have been vaccinated against HPV.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Immediate Vaccination

Administration of dose #1 of 9-valent HPV vaccination at baseline visit, dose #2 at month 2, and dose #3 at month 6

6 months
3 visits (in-person)

Delayed Vaccination

Administration of dose #1 of 9-valent HPV vaccination at month 12, dose #2 at month 14, and dose #3 at month 18

6 months
3 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, including changes in anal carriage of vaccine HPV types and immunogenicity

24 months

Treatment Details

Interventions

  • 9-valent HPV vaccination
Trial Overview The trial is testing the safety and effectiveness of the 9-valent HPV vaccine in preventing recurrence of high-grade anal lesions in HIV-positive MSM. It explores how well this vaccine works as part of their overall health management strategy.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Immediate VaccinationExperimental Treatment1 Intervention
Administration of dose #1 of 9-valent HPV vaccination will be given at baseline visit, dose #2 at month 2, and dose #3 at month 6.
Group II: Delayed VaccinationActive Control1 Intervention
Administration of dose #1 of 9-valent HPV vaccination will be given at month 12, dose #2 at month 14, and dose #3 at month 18.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University Health Network, Toronto

Lead Sponsor

Trials
1,555
Recruited
526,000+

Merck Sharp & Dohme LLC

Industry Sponsor

Trials
4,096
Recruited
5,232,000+
Chirfi Guindo profile image

Chirfi Guindo

Merck Sharp & Dohme LLC

Chief Marketing Officer since 2022

Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business

Robert M. Davis profile image

Robert M. Davis

Merck Sharp & Dohme LLC

Chief Executive Officer since 2021

JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University

Findings from Research

The nonavalent HPV vaccine (9vHPV) has shown over 90% efficacy in preventing cervical, vulvar, and vaginal precancers caused by HPV types 16, 18, and five additional cancer-causing types (31, 33, 45, 52, 58) in Phase III clinical studies.
9vHPV has the potential to prevent up to 93% of cervical cancer cases and has demonstrated lasting antibody responses for at least five years, indicating its long-term effectiveness in reducing the burden of HPV-related cancers.
Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus.Toh, ZQ., Kosasih, J., Russell, FM., et al.[2020]
The nine-valent HPV (9vHPV) vaccine demonstrated comparable immune responses to the quadrivalent HPV (qHPV) vaccine for HPV types 6/11/16/18, while also effectively eliciting immune responses for five additional oncogenic HPV types (31/33/45/52/58) in a study of 500 men aged 16-26.
Both the 9vHPV and qHPV vaccines exhibited similar safety profiles, indicating that the 9vHPV vaccine is a safe and effective option for preventing a broader range of HPV-related diseases.
A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men.Van Damme, P., Meijer, CJLM., Kieninger, D., et al.[2017]
The 9-valent HPV vaccine (9vHPV) is safe and highly effective, showing over 99.8% seroconversion rates for all vaccine types in both groups of a study involving 1054 participants aged 11-15 years.
Administering the 9vHPV vaccine alongside the REPEVAX vaccine did not interfere with the immune response to either vaccine, indicating that this approach can safely reduce the number of vaccination visits needed.
An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age.Kosalaraksa, P., Mehlsen, J., Vesikari, T., et al.[2015]

References

Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands. [2021]
Incidence, Clearance, and Persistence of Anal Human Papillomavirus in Men Who Have Sex With Men Living With Human Immunodeficiency Virus: Implications for Human Papillomavirus Vaccination. [2020]
HPV vaccination and anal high-grade precancerous lesions and cancer: a real-world effectiveness study. [2023]
Sexual healthcare professionals' views on HPV vaccination for men in the UK. [2018]
Prophylactic HPV vaccination and anal cancer. [2022]
Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus. [2020]
A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. [2017]
An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age. [2015]
Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence. [2022]
Spotlight on the 9-valent HPV vaccine. [2018]
9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV. [2022]
12.United Statespubmed.ncbi.nlm.nih.gov
A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls. [2015]
13.United Statespubmed.ncbi.nlm.nih.gov
Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security